Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: Implications for the pathophysiology of vitiligo

Journal of Investigative Dermatology

Volumn 124, Issue 1, 2005, Pages 144-150

  Steitz, Julia ^a   Brück, Jürgen ^a   Lenz, Julia ^a   Büchs, Steffi ^a   Tüting, Thomas ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

CD8+ T cells; Immune tolerance; Melanocytes; TRP2; Vitiligo

Indexed keywords

BINDING PROTEIN; CD4 ANTIGEN; CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TYROSINASE RELATED PROTEIN 2;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; GENE GUN; GENETIC ANALYSIS; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSTIMULATION; MELANOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN; SKIN INFLAMMATION; T LYMPHOCYTE ACTIVATION; VITILIGO;

EID: 11944251002     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2004.23538.x     Document Type: Article

References (36)

1. Alferink J, Tafuri A, Vestweber D, Hallmann R, Hämmerling GJ, Arnold B: Control of neonatal tolerance to tissue antigens by peripheral T cell trafficking. Science 282:1338-1341, 1998
2. Baharav E, Merimski O, Shoenfeld Y, et al: Tyrosinase as an autoantigen in patients with vitiligo. Clin Exp Immunol 105:84-88, 1996
3. Berd D, Mastrangelo MJ, Lattime E, Sato T, Maguire HC Jr: Melanoma and vitiligo: Immunology's Grecian urn. Cancer Immunol Immunother 42:263-267, 1996
4. Bloom MB, Perry-Lalley D, Robbins PF, et al: Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 185:453-459, 1997
5. Bowne WB, Srinivasan R, Wolchok JD, et al: Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 190:1717-1722, 1999
6. Bronte V, Apolloni E, Ronca R, et al: Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res 60:253-258, 2000
7. Brossart P, Goldrath AW, Butz EA, Martin S, Bevan MJ: Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 158:3270-3276, 1997
8. Colella TA, Bullock TN, Russell LB, et al: Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: Implications for tumor immunotherapy. J Exp Med 3:1221-1232, 2000
9. Cui J, Bystryn JC: Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. Arch Dermatol 131:314-318, 1995
10. Dittmar M, Kahaly GJ: Polyglandular autoimmune syndromes: Immunogenetics and long-term follow-up. Clin Endocrinol Metab 88:2983-2982, 2003
11. Dudley ME, Wunderlich JR, Robbins PF, et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854, 2002
12. Fishman P, Merimski O, Baharav E, Shoenfeld Y: Autoantibodies to tyrosinase: The bridge between melanoma and vitiligo. Cancer 79:1461-1464, 1997
13. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML: Construction of adenovirus vectors through Cre-lox recombination. J Virol 71:1842-1849, 1997
14. Hawiger D, Inaba K, Dorsett Y, et al: Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194:769-779, 2001
15. Kemp EH, Gawkrodger DJ, MacNeil S, Watson PF, Weetman AP: Detection of tyrosinase autoantibodies in patients with vitiligo using 35S-labeled recombinant human tyrosinase in a radioimmunoassay. J Invest Dermatol 109:69-73, 1997
16. Lane C, Leitch J, Tan X, Hadjati J, Bramson JL, Wan Y: Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res 64:1509-1514, 2004
17. Lang KS, Caroli CC, Muhm A, et al: HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. J Invest Dermatol 116:891-897, 2001
18. Le Gal FA, Avril MF, Bosq J, et al: Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. J Invest Dermatol 117:1464-1470, 2001
19. Limmer A, Sacher T, Alferink J, et al: Failure to induce organ-specific autoimmunity by breaking of tolerance: Importance of the microenvironment. Eur J Immunol 28:2395-2406, 1998
20. Loftus DJ, Castelli C, Clay TM, et al: Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J Exp Med 184:647-657, 1996
21. Mandelcorn-Monson RL, Shear NH, Yau E, Sambhara S, Barber BH, Spaner D, DeBenedette MA: Cytotoxic T lymphocyte reactivity to gp100, MelanA/ MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J Invest Dermatol 121:550-556, 2003
22. Ogg GS, Rod Dunbar P, Romero P, Chen JL, Cerundolo V: High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 188:1203-1208, 1998
23. Okamoto T, Irie RF, Fujii S, Huang SK, Nizze AJ, Morton DL, Hoon DS: Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol 111:1034-1039, 1998
24. Overwijk WW, Dellemijn TA, Antony PA, et al: Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198:569-580, 2003
25. Overwijk WW, Lee DS, Surman DR, et al: Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4+ T lymphocytes. Proc Natl Acad Sci USA 96:2982-2987, 1999
26. Palermo B, Campanelli R, Garbelli S, et al: Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: The role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 117:326-322, 2001
27. Rosenberg SA: Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18:175-182, 1997
28. Rosenberg SA, White DE: Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 19:81-84, 1996
29. Scheibenbogen C, Hunstein W, Keilholz U: Vitiligo-like lesions following immunotherapy with IFN alpha and IL-2 in melanoma patients. Eur J Cancer 30A:1209-1211, 1994
30. Schreurs MW, Eggert AA, de Boer AJ, et al: Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res 60:6995-7001, 2000
31. Song YH, Connor E, Li Y, Zorovich B, Balducci P, Maclaren N: The role of tyrosinase in autoimmune vitiligo. Lancet 344:1049-1052, 1994
32. Steitz J, Brück J, Gambotto A, Knop J, Tüting T: Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity. Gene Ther 9:208-213, 2002
33. Steitz J, Brück J, Knop J, Tüting T: Adenovirus-transduced DC stimulate cellular immunity to melanoma via a CD4+ T cell-dependent mechanism. Gene Ther 8:1255-1263, 2001
34. Steitz J, Bruck J, Gambotto A, Knop J, Tuting T: Genetic immunization with human tyrosinase-related protein 2: Implications for the immunotherapy of melanoma. Int J Cancer 86:89-99, 2000
35. Stoitzner P, Pfaller K, Stossel H, Romani N: A close-up view of migrating Langerhans cells in the skin. J Invest Dermatol 118:117-125, 2002
36. Yee C, Thompson JA, Roche P, et al: Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of t cell-mediated vitiligo. J Exp Med 192:1637-1644, 2000